Navigation Links
U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced Solid Tumors
Date:10/18/2007

Onco-genomic guided trial design may increase probability of tumor response

and accelerates drug development

SEATTLE, Oct. 18 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTAX: CTIC) and Systems Medicine, LLC (SM), a wholly-owned subsidiary of CTI, today announced the enrollment of the first patient to its complete phase Ib trial of brostallicin used in combination with either bevacizumab or irinotecan, for patients with advanced solid tumors. Combining brostallicin with either bevacizumab or irinotecan is based on existing preclinical data that strongly supports taking these combinations into the clinic. A third treatment arm, which will include brostallicin in combination with an anticancer agent to be identified, will be added to the study. The agent will be identified from ongoing pharmacogenomic investigations using genomic-based search strategies to identify agents that are synergistic with brostallicin.

The trial, being conducted at multiple U.S. Oncology sites, is unique because of the novel "complete" phase I trial design and that genomic-driven discovery is being used to identify at least one of the agents for use with brostallicin. The study design combines a new drug with existing therapies, selected based on genomic profiling, to increase the probability of seeing tumor responses in phase I and may enhance the overall success of the development program. The complete phase I trial design, which was first reported at the 2007 Annual Meeting of the American Society for Clinical Oncology (ASCO), allows several combination phase 1 trials be conducted simultaneously.

"Most new drug approvals in development are in combination with existing regimens by phase III. By utilizing the complete phase I design, it is possible to rapidly explore several genomicly-guided combinations that could speed the development process and potentially bring benefit to more patients," said Daniel D. Von Hoff, M.D., F.A.C.P., Physician-in-Chief and Director of the Clinical Translational Research Division at the Translational Genomics Research Institute (TGen), Chief Scientific Officer of U.S. Oncology. "With its extensive patient screening at multiple sites, U.S. Oncology is uniquely suited to conduct such studies with a single protocol and parallel multiple regimens."

"Extensive preclinical studies demonstrated that brostallicin is synergistic with multiple agents including both bevacizumab and irinotecan," said James A. Bianco, President and CEO of CTI. "This trial is designed to rapidly follow-up that preclinical data in one consolidated phase I study, save time and expense normally associated with the start up of multiple trials, accrue eligible patients rapidly and generate data to better inform the design of future randomized phase II or III trials."

About Brostallicin

Brostallicin, a novel synthetic second-generation DNA minor groove binder, has potent cancer killing activity and has demonstrated synergism in combination with standard cytotoxic agents as well as with newer targeted therapies in preclinical experimental tumors models. Brostallicin binds covalently to DNA within the DNA minor groove interfering with DNA division and leading to tumor cell death. More than 200 patients have been treated with brostallicin in single-agent and combination studies. Brostallicin had predictable and predominantly hematologic toxicities. Activity was demonstrated in a number of solid tumor types. A phase II study of brostallicin in relapsed/refractory soft tissue sarcoma met its pre-defined activity and safety hurdles and resulted in a first-line phase II study that is currently being conducted by the European Organization for Research and Treatment of Cancer (EORTC).

Brostallicin was discovered at Pharmacia and developed by Nerviano Medical Sciences (NMS) the largest pharmaceutical research and development facility in Italy and one of the largest oncology-focused, integrated discovery and development companies in Europe. Following a merger between Pfizer and Pharmacia, the rights to Brostallicin were assigned to NMS which continued its development and ultimately licensed worldwide rights to Systems Medicine.

About Systems Medicine (SM)

In July 2007, CTI acquired Systems Medicine (SM), a privately-held oncology company, in a stock-for-stock merger. SM applies a systems biology approach to drug development, combining pharmacogenomics and bioinformatics with experienced preclinical, clinical, and regulatory expertise to find and exploit a specific cancer's context of vulnerability. Specifically, SM defines the molecular and genetic alterations (context) that cause cancer cells to be particularly sensitive (vulnerable) to a drug or combination of drugs-the context of vulnerability.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit http://www.cticseattle.com.

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect the development of brostallicin include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with brostallicin in particular including, without limitation, the potential failure of brostallicin to prove safe and effective for treatment of solid tumors, determinations by regulatory, patent and administrative governmental authorities, competitive factors, technological developments, costs of developing, producing and selling brostallicin, and the risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by Italian law, CTI is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

Media Contact:

Dan Eramian

T: 206.272.4343

C: 206.854.1200

Susan Callahan

T: 206.272.4472

F: 206.272.4434

E: media@ctiseattle.com

http://www.cticseattle.com/media.htm

Investors Contact:

Leah Grant

T: 206.282.7100

F: 206.272.4434

E: invest@ctiseattle.com

http://www.cticseattle.com/investors.htm


'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Radiation Overdose at the Beatson Oncology Centre
2. Videoconferencing, an impetus to Pediatric Oncology
3. Oncology Drug Pemnat Launched By NATCO
4. United Biotech Launches New Oncology Division
5. Bengal Teenager to Participate in World Oncology Camp
6. CMPMedica Adds Oncology Search Engine to SearchMedica.com
7. Bird Flu: Orissa Initiates Protective Measures
8. Biota Initiates Drug Testing War against Common Cold
9. Russia Initiates Mass Vaccination Of Poultry To Restrict Bird Flu
10. Government Initiates A Program To Curb HIV
11. Alteon Initiates Phase 2 Trial of ALT-2074 in Diabetes and Haptoglobin 2-2
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/18/2017)... ... February 17, 2017 , ... Focused ... innovation in the industry, according to the recent NEJM Catalyst Insights Report on ... of the NEJM Catalyst Insights Council, a qualified group of U.S. executives, clinical ...
(Date:2/18/2017)... , ... February 18, 2017 , ... ... Use Pixel Film Studios ’ ProParagraph Fashion Volume 2 for all ... many other applications. Users can pick and choose from hand-crafted trend-setting designs ...
(Date:2/17/2017)... San Diego, CA (PRWEB) , ... February 17, ... ... new initiative—InvestUp—to focus on foundational and sustainable systems change designed to further positively ... Counties. , “The Board of Trustees has long considered it our duty to ...
(Date:2/17/2017)... ... February 17, 2017 , ... Empowering each person's mental functions, ... each and every seminar, session and class she offers. At the International ... which help energize creativity, focus mental functions, enhance athletic focus and skill sets, ...
(Date:2/17/2017)... , ... February 17, 2017 , ... ... fall 2017 season , Trinity Health and the U.S. Soccer Foundation announced today ... program in underserved communities. Soccer for Success, the Foundation’s soccer mentoring program, teaches ...
Breaking Medicine News(10 mins):
(Date:2/16/2017)... 2017 Absorption Systems, a global leader in ... pleased to announce that its Chief Operating Officer, ... winner of the 2017 Executive Management Award. The award ... driven executives for their creative management vision, leadership philosophy, ... and celebration is on March 8, 2017 at the ...
(Date:2/16/2017)... , Feb. 16, 2017  Aralez Pharmaceuticals Inc. (NASDAQ: ... pharmaceutical company, today announced that executive management will participate ... be held February 22-23, 2017. Adrian Adams , ... Company at 1:35 p.m. local time on Wednesday, February ... archive for the event may be accessed from the ...
(Date:2/16/2017)... Summary Provides understanding and access to ... leading healthcare companies. ... Description The Global Allergy Partnering Terms and Agreements since 2010 ... into by the world,s leading healthcare companies. - ... - Deals listed by company A-Z, industry sector, stage of development, ...
Breaking Medicine Technology: